Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06875310 · ClinicalTrials.gov registry record · Phase 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Mirati Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
630
Enrollment target
20
Study locations

NCT06875310: Recruiting Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Mirati Therapeutics.

NCT06875310 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 630 participants, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06875310, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Mirati Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
630 participants
Enrollment target
20
Study locations

Study Summary

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Placebo
  • DRUG Pemetrexed
  • DRUG Adagrasib

Study Locations (20)

Florida

  • Local Institution - 0052 - Jacksonville
  • Local Institution - 0680 - Ocala
  • Local Institution - 0679 - Orange City
  • Local Institution - 0621 - Palm Bay
  • Florida Clinical Trials Group. - Tamarac
  • Local Institution - 0647 - Tampa

California

  • Local Institution - 0581 - Fullerton
  • Local Institution - 0682 - Loma Linda
  • Local Institution - 0202 - Long Beach
  • Local Institution - 0623 - Santa Barbara

Illinois

  • Local Institution - 0665 - Arlington Heights
  • Local Institution - 0676 - Chicago
  • Local Institution - 0683 - Springfield

Indiana

  • Local Institution - 0684 - Fort Wayne
  • Local Institution - 0423 - Munster

Alabama

  • Local Institution - 0347 - Birmingham

Arkansas

  • Local Institution - 0686 - Springdale

Colorado

  • Local Institution - 0442 - Denver

Georgia

  • Local Institution - 0031 - Marietta

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 2025-04-24
Est. Completion 2032-04-30
Phase Phase 3
Mirati Therapeutics

49 total trials

What NCT06875310 shows while recruiting

NCT06875310 is an interventional study that assigns participants to a tested intervention. The registered 630 participants enrollment target is mid-sized for trials with a published cap, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% higher).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT06875310 names 20 study sites across 9 states, led by Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06875310 about?

NCT06875310 is a clinical study titled "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)". This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mu...

What is the current status of trial NCT06875310?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2025-04-24. Estimated completion is 2032-04-30.

What conditions does trial NCT06875310 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT06875310?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Placebo (DRUG), Pemetrexed (DRUG), Adagrasib (DRUG).

Who is sponsoring clinical trial NCT06875310?

This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06875310 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06875310's enrollment target sits among peer trials

630 22nd of 130 higher than 109 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04704921 · 630 participants · Phase 2

    Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

  • NCT04707729 · 630 participants · NA

    ROX Index for the Timing of Intubation in Nasal High Flow

  • NCT05061550 · 630 participants · Phase 2

    Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • NCT05224440 · 630 participants · NA

    National Sponsorship Program for Transitioning Service Members

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06875310

Source: ClinicalTrials.gov NCT06875310, the US trial registry maintained by the National Library of Medicine. NCT06875310 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.